Noel Heaney, general manager of BMS Biologics Ireland, provides an overview of BMS in Ireland, its exciting new USD 900 million biologics facility in Cruiserath, their innovative HR programs and his five-year-vision for BMS Biologics in Ireland.
BMS has a strong heritage in Ireland dating back to 1964 when it became one of the first API manufacturers here, and recently it announced a significant investment of USD 900 million to build a biologics facility here. Can you first provide an overview of BMS’ existing footprint in Ireland?
This evolution of BMS Ireland is very much in line with our overall company evolution. The company you see today is the product of a BioPharma strategy developed in 2007 to combine the resources, scale and capability of a pharmaceutical company with the speed and focus on innovation of the biotech industry
